In a patient with hyperparathyroidism who cannot tolerate cinacalcet, what alternative treatments are available and should she follow a low‑calcium diet?

Alternative Treatment for Cinacalcet-Intolerant Hyperparathyroidism

For a patient with hyperparathyroidism who cannot tolerate cinacalcet, bisphosphonates (such as alendronate) or denosumab should be offered as alternative medical therapy, particularly if osteoporosis is present, and she should maintain normal calcium intake (800-1000 mg/day) rather than restricting dietary calcium. 1

Medical Treatment Alternatives

First-Line Alternative: Bisphosphonates or Denosumab

When cinacalcet is not tolerated, the 2025 French expert consensus provides clear guidance 1:

• Bisphosphonates (e.g., alendronate) are recommended for patients with osteoporosis
• Denosumab may be particularly useful if there is radius bone involvement
• These medications address the bone complications of hyperparathyroidism even though they don't directly lower PTH levels

Important caveat: While bisphosphonates can increase bone mineral density and lower serum calcium, they may paradoxically increase PTH levels 2. However, they remain a reasonable option when surgery is not possible and cinacalcet cannot be used.

Severe Hypercalcemia Management

If she develops severe hypercalcemia (≥3.5 mmol/L or 140 mg/L), more aggressive treatment is needed 1:

• Intravenous bisphosphonates (zoledronate or pamidronate) after appropriate lab sampling
• Denosumab as second-line if renal function is severely impaired or bisphosphonates are ineffective
• Volume expansion with IV saline (adapted to cardiac/renal function)

Dietary Calcium Recommendations

She should NOT avoid high-calcium foods. This is a critical point that contradicts common misconceptions 1:

• Target calcium intake: 800 mg/day for women under 50 years; 1000 mg/day for women over 50 years
• These are the same recommendations as the general population
• Restricting calcium can worsen bone disease without improving the underlying hyperparathyroidism

The guideline explicitly states that calcium intake should follow general population recommendations, not be restricted 1.

Vitamin D Management

• Target plasma vitamin D concentration should be >30 ng/mL
• 25(OH)Vitamin D supplementation should be prescribed if levels are low
• This applies even in non-operated patients 1

Treatment Algorithm for Cinacalcet Intolerance

1. Assess bone status: If osteoporosis is present → start bisphosphonates or denosumab
2. Maintain normal calcium intake: 800-1000 mg/day based on age and sex
3. Optimize vitamin D: Supplement to achieve levels >30 ng/mL
4. Monitor calcium levels: If calcium rises >0.25 mmol/L above upper limit of normal, consider local destruction techniques only after medical treatment failure 1
5. Reassess surgical candidacy: Surgery remains the definitive treatment if feasible

Common Pitfalls to Avoid

• Don't restrict dietary calcium - this worsens bone disease without treating the underlying problem
• Don't assume all calcimimetics are equivalent - while rare, some patients may tolerate one calcimimetic but not another (though etelcalcetide is IV and primarily for dialysis patients) 3
• Don't use bisphosphonates as monotherapy expecting PTH reduction - they improve bone density but may increase PTH 2
• Don't forget vitamin D optimization - low vitamin D should be corrected even in hyperparathyroidism 1

When to Reconsider Surgery

The guideline emphasizes that surgery remains the gold standard 1. Medical management with bisphosphonates/denosumab is reasonable only when:

• Surgery is contraindicated due to comorbidities
• Patient refuses surgery
• Surgical expertise is not available

Local destruction techniques (ultrasound-guided ablation) should only be considered after failure or intolerance of medical treatment in patients with surgical contraindications 1.